Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.46 |
| ▸ | PPARD | Q03181 | 4/20 | 0.46 |
| ▸ | ACACB | O00763 | 2/20 | 0.46 |
| ▸ | ACACA | Q13085 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | FABP1 | P07148 | 1/20 | 0.45 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 3/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5127221 | 0.90 | PPARD (0.50) | FFAR1PPARDACACBACACAPPARA | |
| SCHEMBL5126743 | 0.89 | FFAR1 (0.53) | FFAR1PPARDACACBACACAPPARA | |
| SCHEMBL5132056 | 0.88 | ACACA (0.49) | FFAR1PPARDACACBACACAPPARA | |
| SCHEMBL14605874 | 0.87 | FFAR1 (0.50) | FFAR1PPARDACACBACACAPPARA | |
| SCHEMBL5129165 | 0.87 | PPARD (0.46) | FFAR1PPARDACACBACACAPPARA | |
| SCHEMBL5129466 | 0.86 | FFAR1 (0.48) | FFAR1PPARDACACBACACAPPARA | |
| SCHEMBL5126060 | 0.85 | RXRA (0.52) | FFAR1PPARDACACBACACAFFAR4 | |
| SCHEMBL5123157 | 0.84 | THRA (0.50) | FFAR1PPARDACACBACACAPPARA | |
| SCHEMBL5122293 | 0.84 | THRA (0.48) | FFAR1PPARDACACBACACAPPARA | |
| SCHEMBL5129079 | 0.83 | FFAR4 (0.51) | FFAR1ACACBACACAFABP1CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249137-A1 | PPAR active compounds | PLEXXIKON INC | 2008-10-09 | — | — | US | disclosed |
| US-20080249137-A1 | PPAR active compounds | PLEXXIKON INC | 2008-10-09 | — | — | US | disclosed |
| US-20080249137-A1 | PPAR active compounds | PLEXXIKON INC | 2008-10-09 | — | — | US | disclosed |
| WO-2007030567-A2 | PPARACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249137-A1 | PPAR active compounds | PPARG, PPARA, PPARD | FFAR1 57/4885PPARD 3/4885ACACB 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.